BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh N, Villoutreix BO. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Comput Struct Biotechnol J 2021;19:2537-48. [PMID: 33936562 DOI: 10.1016/j.csbj.2021.04.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Saha S, Yeom GS, Nimse SB, Pal D, Baig MH. Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/5904261] [Reference Citation Analysis]
2 Sugiyama MG, Cui H, Redka DS, Karimzadeh M, Rujas E, Maan H, Hayat S, Cheung K, Misra R, McPhee JB, Viirre RD, Haller A, Botelho RJ, Karshafian R, Sabatinos SA, Fairn GD, Madani Tonekaboni SA, Windemuth A, Julien JP, Shahani V, MacKinnon SS, Wang B, Antonescu CN. Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease. Sci Rep 2021;11:23315. [PMID: 34857794 DOI: 10.1038/s41598-021-02432-7] [Reference Citation Analysis]
3 Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. Front Pharmacol 2021;12:704205. [PMID: 34867318 DOI: 10.3389/fphar.2021.704205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hok L, Rimac H, Mavri J, Vianello R. COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymes. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.02.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang Z, Guo K, Gao P, Pu Q, Li C, Hur J, Wu M. Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications. Precis Clin Med 2021;4:215-30. [PMID: 34993416 DOI: 10.1093/pcmedi/pbab022] [Reference Citation Analysis]
6 Jain S, Talley DC, Baljinnyam B, Choe J, Hanson Q, Zhu W, Xu M, Chen CZ, Zheng W, Hu X, Shen M, Rai G, Hall MD, Simeonov A, Zakharov AV. Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. ACS Pharmacol Transl Sci 2021;4:1675-88. [PMID: 34608449 DOI: 10.1021/acsptsci.1c00176] [Reference Citation Analysis]
7 Wang Z, Yang L, Zhao XE. Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. Comput Struct Biotechnol J 2021;19:4684-701. [PMID: 34426762 DOI: 10.1016/j.csbj.2021.08.029] [Reference Citation Analysis]
8 Sencanski M, Perovic V, Milicevic J, Todorovic T, Prodanovic R, Veljkovic V, Paessler S, Glisic S. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach. ChemistryOpen 2022;11:e202100248. [PMID: 35103413 DOI: 10.1002/open.202100248] [Reference Citation Analysis]